EUVIMEDEUVIMED entdecken
Crossref

Association Between PD-L1 Score and the Outcomes of Consolidation Durvalumab in a Large Nationwide Series of Patients With Stage III NSCLC Treated With Chemoradiotherapy

Ronald Damhuis, Idris Bahce, Suresh Senan

Clinical Lung Cancer · 2024

DOI: 10.1016/j.cllc.2024.07.013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lung Cancer, 2024. Verfasst von Ronald Damhuis und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL) Utrecht, The Netherlands. Electronic address: r.damhuis@…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Chemoradiotherapy, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The Pacific trial reported improved outcomes when durvalumab was administered following concurrent chemoradiotherapy (CRT) for stage III NSCLC. Post-hoc subgroup analysis did not show favorable results for PD-L1 negative cases. We compared nationwide survival data with the trial outcomes, and evaluated the influence of PD-L1. PATIENTS AND METHODS: Data from the Netherlands Cancer Registry were queried regarding patients with clinical stage III who underwent CRT, either by concurrent or sequential administration. Predictors for the use of consolidation treatment with durvalumab were evaluated by tabulations and logistic regression analysis. Overall survival (OS) was calculated from start of radiation or start of durvalumab and was stratified by PD-L1 score. RESULTS: Between 2017 and 2021, application of consolidation durvalumab increased from 2% to 21%, 40%, 57%, 62%, respectively. In the period 2020-2021, durvalumab use was more frequent among patients with younger age, concurrent CRT, better performance score and proton radiation, but was irrespective of PD-L1 score. For patients receiving durvalumab (n = 1639), the 4-year OS was 53% overall (95%CI 50-57), and it was 56% (95%CI 52-60) after concurrent CRT. Four-year OS was considerably better for the PD-L1 subgroup ≧50% at 67% (95%CI 59-73), and it was similar for PD-L1 subgroups 0 and 1-49, at 51% (95%CI 42-58) and 46% (95%CI 39-54), respectively. CONCLUSION: In real-world clinical practice, survival outcomes were equivalent to results from trial series. Overall survival in patients with negative PD-L1 was similar to the survival in patients with PD-L1 1-49, questioning the restrictions imposed by the European Medicines Agency.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenChemoradiotherapyLung NeoplasmsCarcinoma, Non-Small-Cell LungAntibodies, MonoclonalNeoplasm StagingHumansMaleFemaleAgedMiddle AgedAntineoplastic Agents, ImmunologicalNetherlandsSurvival RateAdultConsolidation ChemotherapyFollow-Up StudiesPrognosis

Stichwörter der Autor:innen

Cancer registryOverall survivalProton radiationReal-worldTreatment delay

Substanzen

durvalumabB7-H1 AntigenCD274 protein, humanAntibodies, MonoclonalAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL) Utrecht, The Netherlands. Electronic address: r.damhuis@iknl.nl.
  • Department of Pulmonary Medicine, Amsterdam University Medical Center location VUmc, Amsterdam, The Netherlands; Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, The Netherlands.
  • Department of Radiation Oncology, Amsterdam University Medical Center location VUmc, Amsterdam, The Netherlands; Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, The Netherlands.

Zitieren

APA

Damhuis, R., Bahce, I., & Senan, S. (2024). Association Between PD-L1 Score and the Outcomes of Consolidation Durvalumab in a Large Nationwide Series of Patients With Stage III NSCLC Treated With Chemoradiotherapy. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2024.07.013

Vancouver

Damhuis R, Bahce I, Senan S. Association Between PD-L1 Score and the Outcomes of Consolidation Durvalumab in a Large Nationwide Series of Patients With Stage III NSCLC Treated With Chemoradiotherapy. Clinical Lung Cancer. 2024. doi:10.1016/j.cllc.2024.07.013

BibTeX
@article{Damhuis2024,
  author = {Damhuis, Ronald and Bahce, Idris and Senan, Suresh},
  title = {Association Between PD-L1 Score and the Outcomes of Consolidation Durvalumab in a Large Nationwide Series of Patients With Stage III NSCLC Treated With Chemoradiotherapy},
  journal = {Clinical Lung Cancer},
  year = {2024},
  doi = {10.1016/j.cllc.2024.07.013}
}
Kostenlos starten →